)
Peter Noymer, PhD
CEO
153 Therapeutics, Inc.
Peter Noymer, PhD, is a co-founder and CEO of 153 Therapeutics, a UCSF neuroscience spinout. Peter also serves as Executive Chairman of PyrAmes, a Stanford digital health spinout. Prior to co-founding 153, he served as an EIR with UCSF Innovation Ventures, helping to establish key POC milestones that led to company formation. Earlier, Peter served as CEO of Kedalion Therapeutics (acquired by Novartis), COO at SteadyMed Therapeutics (acquired by United Therapeutics), and VP of Product R&D at Alexza Pharmaceuticals (acquired by Grupo Ferrer). Peter holds MS and PhD degrees from MIT, and a BS degree from Princeton.
Sessions
-
24-Jun-20265B153 Therapeutics, Inc.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}